Nasdaq · Biotech stocks database
XRTX — XORTX Therapeutics Inc. ☆
XRTX (XORTX Therapeutics Inc.) stock: $0.91, $1.7M market cap, $14.8M cash, -$13.1M EV, $1.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Our registered office is located at 250 Howe Street, 20 th Floor, Vancouver, British Columbia, V6C 3R8. Our operations office and mailing address is 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 and our telephone number is (403) 455-7727. Our website address is www.xortx.com.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $14.8M Debt $0.0M Net cash $14.8M Enterprise value -$13.1M Basic shares 1.4M shares Fully diluted shares 1.4M shares Fully diluted market cap $1.3M Cash per share $10.67
Cash figures as of 2021-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-06-30.
Price history Loading XRTX daily closes…
Loading price history…
Next catalyst XRx-026 · Est. Nov 15, 2026 · quarter midpoint · guided Now All upcoming catalysts →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide GUIDED Est. Nov 15, 2026 Now quarter midpoint
XRx-026IND submission for XRx-026 for gout
Not disclosed XRx-026 Q4 2026
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.